Abstracts tagged "interferon"

Abstract Number: 2456 • ACR Convergence 2024
High Levels of Circulating IFNα Are Associated with Increased Mortality in Patients with Diffuse Cutaneous Systemic Sclerosis
François Maillet¹, Carine Schmidt¹, Vincent Bondet², Alexandre Bense¹, Darragh Duffy³, Luc Mouthon¹, Mathieu Paul Rodero⁴ and Benjamin Chaigne⁵, ¹AP HP, Paris, France, ²INSERM PAsteur Institute, Paris, France, ³Inserm Pasteur Institue, Paris, France, ⁴Université Paris CIté, Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques, Faculté des Saint-Pères, Paris, France, ⁵Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France de l’Est et de l’Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, Ile-de-France, France
Background/Purpose: Systemic sclerosis (SSc) is a connective tissue disease characterized by skin and organ fibrosis, autoimmunity, and vasculopathy. Although its pathophysiology remains unclear, recent data…
Abstract Number: 0020 • ACR Convergence 2024
CD14 Deficiency Protects Against TLR4/LPS-mediated Inhibition of Osteoclastogenesis
Lance Murphy¹, Kevin Burt², Vu Nguyen³, Baofeng Hu², Robert Mauck³ and Carla Scanzello², ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia
Background/Purpose: Osteoarthritis is associated with bone changes such as subchondral sclerosis, bone marrow lesions, and osteophyte formation (Donel S, 2019). Prior work has demonstrated that…
Abstract Number: 1266 • ACR Convergence 2024
Anti-Mitochondrial Antibodies Associate with Disease Activity and IFNα Expression in Childhood-onset Systemic Lupus Erythematosus
Marina Barguil Macedo¹, Javad Wahadat², Albin Bjoerk³, Sylvia Kamphuis², Marjan Versnel² and Christian Lood¹, ¹University of Washington, Seattle, WA, ²Erasmus University Medical Center, Rotterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Extracellular mitochondria may represent a source of antigenic burden in autoimmune disorders, such as in systemic lupus erythematosus (SLE), in which those organelles, released…
Abstract Number: 1778 • ACR Convergence 2024
A Novel Variant in IRAK2 Results in Immune Dysregulation in Systemic Juvenile Idiopathic Arthritis (sJIA)
Mariana Correia Marques¹, Brooke Boyd², Alana Platukus³, Elizabeth Schmitz², Hiroto Nakano², Faiza Naz⁴, Anthony Cruz¹, Stefania Dell'Orso⁴, Zuoming deng⁴ and Michael Ombrello⁵, ¹National Institutes of Health, Bethesda, MD, ²Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ³1Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Lung disease (LD) is poorly understood complication of Still’s disease with high fatality. HLA-DRB1*15 is a strong risk factor for the development of this…
Abstract Number: 2518 • ACR Convergence 2024
Behçet’s Disease Immune Landscape Exhibits a Universal NF-kB-mediated Hyperactivation Pattern with Cell-specific TNFAIP3 Responses and a Superimposed IFN-regulated Endotype
Yesim Ozguler¹, Olivier Manches², Didar Ucar³, Ziyan Lin², Alireza Khodadadi-Jamayran², Aristotelis Tsirigos², Gulen Hatemi¹ and Johannes Nowatzky⁴, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²NYU Grossman School of Medicine, New York, NY, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: The immune landscape of Behçet’s disease (BD) remains ill-defined, lacking a unifying picture, precise disease phenotype-endotype correlations, and an understanding of immunity at target…
Abstract Number: 0092 • ACR Convergence 2024
A New Generation Mesenchymal Stromal Cell (MSC)-based Cell Therapy Using Design of Experiments Halts Pristane Induced Glomerulosclerosis
Hulya Bukulmez¹, Adrienne Dennis², kristine Highland³ and Steven N. Emancipator⁴, ¹MetroHealth Medical Center, Case Western Reserve, Pepper Pike, OH, ²MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ³Cleveland Clinic Foundation, Cleveland, OH, ⁴Case Western Reserve University, Cleveland, OH
Background/Purpose: MSCs, exposed to a disease-specific cytokine profile, can accurately sense the composition of the inflammatory microenvironment. We have harnessed this adaptive ability of MSCs…
Abstract Number: 1426 • ACR Convergence 2024
Single Cell RNA-Seq Characterization of Circulating Immune Cells in Sjogren’s Syndrome: Comparison to SLE and Rheumatoid Arhtritis
Alejandro Gomez-Gomez¹, yolanda Guillen², Paloma Vela Casasempere³, María Paula álvarez Hernández⁴, Ignacio Brana Abascal⁵, Mónica Fernández Castro⁶, Maria López Lasanta¹, José María Pego-Reigosa⁷, Carlos Marras⁸, María García-Villanueva⁹, Francisco Blanco¹⁰, Patricia Carreira¹¹, Carolina Perez-Garcia¹², Íñigo Rúa-Figueroa¹³, Hugo F Avalos bogado¹, Natalia Boix Martí¹, Eric Kirkegaard-Biosca¹⁴, iago álvarez Sáez¹⁵, Nuria Palau¹⁶, Raül Tortosa¹⁶, Jesús Tornero Molina¹⁷, Antonio Fernandez Nebro¹⁸, Jaime Calvo-Alén¹⁹, Juan Cañete²⁰, Damiana Alvarez-Errico², Ernest Choy²¹, Holger Heyn²², Antonio Julia²³, Sara Marsal barril¹ and Jose Luis Andreu²⁴, and on behalf of SSAD and DocTIS consortia, ¹Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, ²Imidomics, Inc, Barcelona, Spain, ³Hospital General Universitario de Alicante , Rheumatology, Alicante, Spain, ⁴Hospital universitario de la Princesa. IIS-Princesa, Rheumatology, Madrid, Madrid, Spain, ⁵Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain, ⁷Galicia Health Service (SERGAS), Vigo, Spain, ⁸Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁹Hospital Ramón y Cajal, MADRID, Madrid, Spain, ¹⁰Complejo Hospitalario Universitario de A Coruña , Rheumatology, A Coruña, Spain, ¹¹Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ¹⁴Hospital Universitari Vall d´Hebron, Ophtalmology, Barcelona, Spain, ¹⁵Hospital Universitari Vall d´Hebron, Maxillofacial Surgery, Barcelona, Spain, ¹⁶Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, ¹⁷Sociedad Española de Reumatologia, Rheumatology, Madrid, Spain, ¹⁸Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, ¹⁹Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ²⁰Hospital Clinic an IDIBAPS, Barcelona, Spain, ²¹Cardiff University School of Medicine, Cardiff, United Kingdom, ²²Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, ²³Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain
Background/Purpose: Primary Sjögren’s Syndrome (pSS) shares with SLE and RA features including their predominance in women, immunological characteristics and genetic risk background. Hence, to dissect…
Abstract Number: 1792 • ACR Convergence 2024
CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus
Lauren Robinson¹, Preetha Balasubramanian², Zurong Wan², Juan Rodriguez Alcazar², Marina Lima Silva Santos², Lynnette Walters³, Jeanine Baisch², Karen Onel⁴, Tracey Wright⁵, Virginia Pascual⁶ and Simone Caielli², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Scottish Rite Hospital for Children, Allen, TX, ⁴HSS, New York, NY, ⁵UT Southwestern, Plano, TX, ⁶Weill Cornell Medical College, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
Abstract Number: 2540 • ACR Convergence 2024
Characterizing the Functional Role of Type I Interferons in Inflammatory Arthritis
Mary Huang, Richard Bell, Toolika Singh and Lionel Ivashkiv, Hospital for Special Surgery, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by synovial inflammation due to cellular infiltration and inflammatory mediators. Type I interferons (IFN) have…
Abstract Number: 0093 • ACR Convergence 2024
Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure
Benjamin Klein¹, Kelsey E. McNeely², Debbie Colesa², Yiqing Gao², Nguyen Thi Kim Nguyen², Johann Gudjonsson¹ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Michigan Medicine, Ann Arbor, MI
Background/Purpose: Skin involvement is the most common organ manifestation in systemic lupus erythematosus (SLE), and exacerbation of cutaneous lupus (CLE) can precede systemic disease flares.…
Abstract Number: 1430 • ACR Convergence 2024
C57BL/6.NOD-Aec1Aec2 Mice Recapitulate Sjögren’s Serology Better Than NOD.B10Sn-H2b Models and JAK Inhibitor Treatment Improves Immunoglobulins and Salivary Gland Inflammation but Not Salivary Flow in Sjögren’s Mice
Sara McCoy¹ and Ilya Gurevic², ¹University of Wisconsin, Middleton, WI, ²University of Wisconsin, Madison
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease in which interferons (IFNs) are believed to play a major role/ JAK inhibitors (JAKinibs) block IFN…
Abstract Number: 1793 • ACR Convergence 2024
SLE Patient Serum and SLE-associated Danger Signals Impair Efferocytosis in Human Macrophages
Jessica Shannon and Rafael de Queiroz Prado, AstraZeneca, Gaithersburg, MD
Background/Purpose: Efficient clearance of apoptotic cells, known as efferocytosis, plays a pivotal role in maintaining self-tolerance. Dysfunction in efferocytosis is implicated in the pathogenesis of…
Abstract Number: 2547 • ACR Convergence 2024
Neurophysiological Phenotypes Are Uncoupled from Toll-like Receptor-Mediated Peripheral Disease in a Mouse Model of Neuropsychiatric Symptoms of Systemic Lupus Erythematosus
Cecilia Stumpf¹, Vanessa Rodriguez¹ and Carla Cuda², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with diverse clinical presentations, including neuropsychiatric symptoms (NPSLE). Despite being a major cause of morbidity…
Abstract Number: 0328 • ACR Convergence 2024
IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease
Melissa Leeolou¹, Lorinda Chung², Kavita Sarin³ and david fiorentino⁴, ¹Stanford University School of Medicine, Redwood City, CA, ²Stanford University, Woodside, CA, ³Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA
Background/Purpose: Type I interferon (IFN) plays a role in the pathogenesis of dermatomyositis (DM) and correlates with measures of disease activity. Melanoma differentiation-associated gene 5…
Abstract Number: 1497 • ACR Convergence 2024
Type I Interferon Status and Clinical Manifestations in a Large Cohort of Patients with Systemic Lupus Erythematosus
Justin Smith¹, Laura Patricia Whittall Garcia², Dennisse Bonilla², Qixuan Li², Robert Terbrueggen³, Hemani Wijesuriya³, Ian Richards³, Aviva Jacobs³, Joan Wither², Dafna Gladman⁴ and Zahi Touma⁵, and DxTerity, ¹University of Toronto, Toronto, AB, Canada, ²University Health Network, Toronto, ON, Canada, ³DxTerity Diagnostics Inc., Torrance, CA, ⁴University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Type I interferons (IFN) are pivotal in the pathogenesis of SLE, with studies showing high IFN gene signature (IGS) status associated with certain organ…

« Previous Page
1
…
4
5
6
7
8
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].